Healthcare business intelligence: Boston Scientific (BSX) closed on its acquisition of C.R. Bard‘s Bard EP Nov. 1. According to a company statement, the addition of Bard’s advanced therapeutic catheters, diagnostic catheters, electrophysiology recording systems and intracardiac access devices will help BSX address the $2.5 billion EP market, which is growing by as much as 10 percent yearly. It cost the medical device company $275 million in cash — a pretty penny for Bard, which only generated $111 million in sales last year, according to a release.
Boston Scientific also expects the additional capabilities brought by the acquisition, including extended reach in strategic global markets, will help accelerate launches of key EP technologies such as the recently approved IntellaTip MiFi™ XP ablation catheter and next-generation Rhythmia™ Mapping System.
Bard EP became part of Boston Scientific’s already existing Rhythm Management unit.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Follow MedCity News on Facebook and Twitter for more updates.
